JP2022016960A - Composition for extending health life - Google Patents

Abstract

To provide a new health functionality of probiotics.SOLUTION: A composition for extending health life contains Bifidobacterium bacteria and Lacticaseibacillus bacteria. Preferably the composition can extend the health life by preventing and/or improving frailty.SELECTED DRAWING: None

Description

The present invention relates to compositions for extending healthy life expectancy.

In recent years, attention has been focused on the relationship between intestinal bacteria and health, and research is being conducted all over the world. Known as a term related to improving the intestinal environment, "probiotics" generally refers to living microorganisms that have beneficial effects on humans by improving the balance of the intestinal flora.
In addition, there is "prebiotics" that assimilate such probiotics, which are not decomposed and absorbed in the upper part of the digestive tract and become a selective nutrient source for beneficial bacteria that coexist in the large intestine and their proliferation. Generally means anything that promotes, improves and maintains the intestinal flora composition of the large intestine to a healthy balance, and helps to promote and maintain human health.

Bifidobacterium spp. (So-called bifidobacteria) and lactic acid bacteria are known as major probiotics.
Bifidobacterium spp. Have been reported to have various beneficial effects on hosts such as humans, such as prevention of diarrhea, reduction of harmful bacteria and toxic compounds, immunomodulation, and anticarcinogenic activity ( Non-Patent Documents 1 to 3).
Some lactic acid bacteria can show preventive and protective effects against various infectious diseases by activating cell-mediated immunity of the host and enhancing the secretion of immune substances from the mucous membranes of the intestinal tract and respiratory organs. It has been reported (Non-Patent Documents 4 to 7). In addition, strains excellent in their action have also been found (Patent Documents 1 and 2).

International Publication 2012/133827 International release 2015/004949

S. Fukuda et al., Nature, 2011, 469, 543-547. S. Fanning et al., PNAS, 2012, 109 (6), 2108-2113. Sivan A. et al., Science. 2015, 350 (6264), 1084-1089. Delcenserie, V. et al., Curr. Issues Mol. Biol. (2008) 10: 37-54. Hori, T. et al., Clin. Diagn. Lab. Immunol. (2002) 9: 105-108. Takeda, K. et al., Clin. Exp. Immunol. (2006) 146: 109-115. Ogawa, T., Clin. Exp. Immunol. (2006) 143: 103-109.

There are many unknowns about the functionality of probiotics, and the changes in functionality when multiple types of probiotics are combined are still under research.
Under such circumstances, it is an object of the present invention to find and provide new health functionality of probiotics.

As a result of diligent research to solve the above problems, the present inventors have an effect of extending healthy life expectancy in a composition containing a combination of a bacterium belonging to the genus Bifidobacterium and a bacterium belonging to the genus Bifidobacterium. We found that and came to complete the present invention.

That is, the present invention is a composition for extending healthy life expectancy, which contains a bacterium belonging to the genus Bifidobacterium and a bacterium belonging to the genus Lacticaseibacillus.
The bacterium belonging to the genus Bifidobacterium in the present invention is preferably Bifidobacterium longum. Further, the Bifidobacterium longum in the present invention is preferably Bifidobacterium longum NITE BP-026.
21.
The bacterium belonging to the genus Lacticaseibacillus in the present invention is preferably Lacticaseibacillus paracasei. Further, the Lactobacillus paracasei in the present invention is Lactobacillus paracasei NITE BP-01633.
Is.
The Bifidobacterium bacterium and / or the Lactica zeibacillus bacterium in the present invention may be a live bacterium and / or a dead bacterium, respectively.
The composition of the present invention preferably further contains prebiotics.
The prebiotics are preferably lactulose.
The extension of healthy life expectancy in the present invention is preferably due to the prevention and / or improvement of flail.
The composition of the present invention is preferably a food or drink.

According to the present invention, the effect of extending healthy life expectancy can be obtained by preventing or improving frailty. Therefore, it can contribute to living a social life while maintaining physical and mental health in an aging society.

Next, the present invention will be described in detail. However, the present invention is not limited to the following embodiments, and can be freely changed within the scope of the present invention.

The composition of the present invention contains a bacterium of the genus Bifidobacterium and a bacterium of the genus Bifidobacterium. In the present invention, the bacterium belonging to the genus Bifidobacterium may be contained in one or more kinds, and the bacterium belonging to the genus Bifidobacterium may be contained in one or more kinds in combination.

Bifidobacterium genus bacteria are not particularly limited, but Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis,
(Reclassified as Bifidobacterium longum subspecies infantis), Bifidobacterium bifidum, Bifidobacterium adolescentis, Bifidobacterium catenuratum (Bifidobacterium catenulatum), Bifidobacterium pseudocatenulatum, Bifidobacterium animalis, Bifidobacterium lactis, and Bifidobacterium pseudocatenulatum. (Bifidobacterium pseudolongum).

More specifically, Bifidobacterium longum BB536 can be mentioned. Bifidobacterium Longum BB536 is the National Institute of Technology and Evaluation Patent Microorganisms Depositary (NPMD) (〒292-0818).
An international deposit was made on January 26, 2018 at Kazusakamatari Room 2-5-8 122, Kisarazu City, Chiba Prefecture, with the NITE BP-02621 accession number based on the Budapest Treaty. Bifidobacterium longum subsp. Longum ATCC BAA-999 (number: ATCC BAA-999), which is the same bacterium as this, is A.
merican Type Culture Collection (ATCC; USA, 2)
0110, Virginia, Manassas, University Boulevard 10801 (108)
01 University Boulevard, Manassas, VA 2011
0, United States of America)) to ATCC BAA-9
It is available as 99 (see, for example, Japanese Patent Application Laid-Open No. 2012-223134).

More specifically, Bifidobacterium bleve M-16V can be mentioned. Bifidobacterium Breve M-16V has been deposited with NPMD on January 26, 2018 under the accession number NITE BP-02622 under the Budapest Treaty. For example, "Bifidobacterium Breve M-16V" manufactured by Morinaga Milk Industry Co., Ltd., which is available as a commercially available product, may be used.
Further, more specifically, Bifidobacterium Breve MCC1274 is also mentioned as Bifidobacterium Breve. Bifidobacterium Breve MCC1274 was issued on August 25, 2009 by the National Institute of Advanced Industrial Science and Technology, Patent Organism Depositary (currently, National Institute of Technology and Evaluation, Patent Organism Depositary (IPOD) (〒292). -0818 Kazusakamatari, Kisarazu City, Chiba Prefecture, Room 2-5-8, Room 120) has been deposited internationally under the Budapest Treaty with the accession number FERM BP-11175.

More specifically, Bifidobacterium longum subspecies infantis M-63 can be mentioned as Bifidobacterium infantis. Bifidobacterium Longum Subspecies Infantis M-63 is 2018
It is synonymous with Bifidobacterium Infantis M-63, which has been deposited with NPMD on January 26, 2014 under the accession number NITE BP-02623 under the Budapest Treaty.

Among these Bifidobacterium spp., Bifidobacterium longum is more preferable, and among them, Bifidobacterium longum BB536 (accession number: NITE).
BP-02621) is particularly preferable.

Bacteria belonging to the genus Lacticaseibacillus were previously classified into the genus Lactobacillus, but in 2020, according to the rules (ICNP) of the International Code of Nomenclature and Evolutionary Microbiology. Refers to bacteria reclassified into the genus Lacticaseibacillus in (IJSEM) magazine.
The new classification, Lacticaseibacillus casei, includes Lacticaseibacillus casei, Lacticaseibacillus paracasei, and Lacticaseibacillus rhamnosus.

Lacticaseibacillus casei, more specifically, Lactobacillus casei YI
Examples thereof include T9029 (FERM BP-1366) and Lactobacillus casei ATCC393.
Lactobacillus casei YIT9029 is an old class Lactobacillus bacterium, and has been deposited internationally with the IPOD under the accession number of FERM BP-01366 based on the Budapest Treaty.
Lactobacillus casei ATCC393 is available from the American Type Culture Collection (ATCC; address 12301 Parklawn Drive, Rockville, Maryland 20852, United States of America).

More specific examples of Lactobacillus paracasei include Lactobacillus paracasei MCC1849, Lactobacillus paracasei MCC1375, Lactobacillus paracasei KW3110, and Lactobacillus paracasei WON0604.
Lactobacillus paracasei MCC1849 was deposited with NPMD as an old class Lactobacillus bacterium under the accession number of NITE P-01633 on June 6, 2013, based on the Budapest Treaty on January 31, 2014. It was transferred to the international deposit and given the deposit number of NITE BP-01633.
Lactobacillus paracasei MCC1375 is a bacterium belonging to the genus Lactobacillus, which is an old classification, and was sent to the Patent Organism Depositary Center (currently IPOD) of the Industrial Technology Research Institute on November 5, 2010 with the accession number of FERM BP-11313. An international deposit was made under the Budapest Treaty.
Lactobacillus paracasei KW3110 has been deposited internationally under the Budapest Treaty with the accession number of FERM BP-08634 to the IPOD. casei L1
It can also be obtained from the Japan Dairy Technical Association as 4 strains.
Lactobacillus paracasei WON0604 is an international deposit under the Budapest Treaty with the accession number of FERM BP-11468 to the IPOD.

More specific examples of Lacticaseibacillus ramnosus include Lactobacillus ramnosus LCS742 and Lactobacillus ramnosus ATCC53103.
Lactobacillus LCS742 is from Morinaga Milk Industry Co., Ltd.
The one sold as rhamnosus LCS-742 is available (see, for example, Japanese Patent Publication No. 2009-522280).
Lactobacillus ramnosus ATCC53103 is available from the American Type Culture Collection.
Among these lactobacillus spp., Lactobacillus paracasei is more preferable, and among them, Lactobacillus paracasei MCC1849 (accession number: NIT).
EBP-01633) is particularly preferable.

For each of the above-mentioned strains of Bifidobacterium spp. And Lactica zeibacillus spp., The strain itself that has been deposited or registered with a predetermined institution under the name of the bacterium (hereinafter, for convenience of explanation, "deposited strain"". It is not limited to (also referred to as), and strains substantially equivalent thereto (also referred to as “derivative strain” or “derivative strain”) are also included. That is, the stock itself is not limited to the stock itself deposited with the depositary institution with the deposit number, and the stock substantially equivalent thereto is also included. Regarding bacteria, the "strain substantially equivalent to the above-mentioned deposit strain" belongs to the same species as the above-mentioned deposit strain, and the similarity of the genome sequence with the above-mentioned deposit strain (Average Nucleotide Identity value) is preferably 99. .0% or more,
A strain having 99.5% or more, more preferably 100% identity, and preferably having the same mycological properties as the deposited strain. With respect to bacteria, a strain substantially equivalent to the above-mentioned deposit strain may be, for example, a derivative strain having the deposit strain as a parent strain. Derivative strains include strains bred from deposited strains and strains naturally generated from deposited strains. Examples of the breeding method include modification by a genetic engineering method and modification by mutation treatment. Mutation treatment includes irradiation with X-rays, irradiation with ultraviolet rays, and treatment with mutant agents such as N-methyl-N'-nitro-N-nitrosoguanidine, ethylmethanesulfonate, and methylmethanesulfonate. Will be. Examples of naturally occurring strains from the deposited strains include strains naturally occurring during the use of the deposited strains. Examples of such a strain include a mutant strain naturally generated by culturing a deposited strain (for example, subculture). The derivative strain may be constructed by one kind of modification, or may be constructed by two or more kinds of modifications.

As the bifidobacteria and lacticase bacillus bacteria contained in the composition of the present invention, commercially available products may be used, those obtained by appropriately producing them may be used, or the above-mentioned bacteria are cultured. The obtained one may be used.
The culture method is not particularly limited as long as the Bifidobacterium bacterium or the Lactica zeibacillus bacterium can grow respectively. As the culturing method, for example, the methods usually used for culturing Bifidobacterium spp. Or Lactica zeibacillus spp. Can be used as they are or modified as appropriate. The culture temperature may be, for example, 25 to 50 ° C, preferably 35 to 42 ° C. The culture can be preferably carried out under anaerobic conditions, and can be carried out, for example, while aerating an anaerobic gas such as carbon dioxide gas. In addition, the culture can also be carried out under slightly aerobic conditions such as liquid static culture. Culturing can be carried out, for example, until the bacterium grows to a desired degree.

The medium used for culturing is not particularly limited as long as the bacteria of the genus Bifidobacterium or the bacterium of the genus Bifidobacterium can grow. As the medium, for example, a medium usually used for culturing the bacteria can be used as it is or after being appropriately modified. That is, as the carbon source, for example, saccharides such as galactose, glucose, fructose, mannose, cellobiose, maltose, lactose, sucrose, trehalose, starch, starch hydrolysate, and waste sugar honey can be used depending on the assimilation property. .. As the nitrogen source, for example, ammonium salts such as ammonia, ammonium sulfate, ammonium chloride and ammonium nitrate and nitrates can be used. Further, as the inorganic salts, for example, sodium chloride, potassium chloride, potassium phosphate, magnesium sulfate, calcium chloride, calcium nitrate, manganese chloride, ferrous sulfate and the like can be used. Further, organic components such as peptone, soybean flour, defatted soybean meal, meat extract and yeast extract may be used. In addition, as the medium usually used for culturing the bacteria, specifically, a fortified Clostridia medium (Reinforced Clostridial medium), an MRS medium (de Man, Rogosa, and Sharpe medium), an mMRS medium (modified MRS medium), and a TOSP. Medium (TOS propionate medium), TOSP Mup medium (TOS propionate mupirocin medium), GAM (Gifu Anaerobic)
Medium) medium, YCFA (Yeast Extract-casein Hydrolysate Acid) medium and the like can be mentioned.

The morphology of the bacterium Bifidobacterium and the bacterium belonging to the genus Bifidobacterium contained in the composition of the present invention may be independently any of a bacterial cell, a culture of the bacterium, and a treated product of the bacterium.
The bacterial cell may be, for example, a live bacterial cell, a dead bacterial cell (including a damaged bacterial cell), or a mixture of a live bacterial cell and a dead bacterial cell. Bifidobacterium spp. And Lactica zeibacillus spp. May be independently selected from live cells, dead bacteria, and mixtures thereof. In a preferred embodiment, the bacterium belonging to the genus Bifidobacterium is contained in the composition of the present invention as a viable cell, and the bacterium belonging to the genus Bifidobacterium is contained as a killed bacterium in the composition of the present invention.
As the bacterial culture, for example, the culture obtained by the culture may be used as it is, the culture may be diluted or concentrated and used, or the bacterial cells recovered from the culture may be used. Further, as the culture, a culture supernatant or a culture fraction may be used. When the culture supernatant is used, for example, the supernatant of the culture solution obtained by culturing in GAM medium at 37 ° C. for 16 hours can be preferably used.
As the processed product of bacteria, a product obtained by subjecting a bacterial cell or a culture to crushing, heating, freeze-drying, or spray-drying, and a diluted product, a dried product, or a fraction thereof can be used.

The content of each of the bacteria of the genus Bifidobacterium and the bacterium of the genus Bifidobacterium in the composition of the present invention is not particularly limited, but for example, the amount of the bacterial cells is 1.0 × 10 ⁴ cfu per 1 g of the composition. The above is preferable, and more preferably 1.0 × ¹⁰⁷ cfu or more of bacterial cells may be contained. In addition, cfu is a colony forming unit (Co).
It refers to a long forming unit). In the present specification, for example, it can be the value when cultured at 38 ° C. in a solid medium containing 10% by mass of reduced skim milk powder. Further, when the cells are dead cells, cfu can be replaced with individual cells (cells).
When the culture supernatant is used as the culture of the bacterium, it is preferably 0.1 to 100% by mass, more preferably 1 to 90% by mass, and further preferably 10 to 80% by mass of the whole composition. Can be.
The ratio of the contents of the Bifidobacterium bacterium and the Lactica zeibacillus bacterium in the composition of the present invention is not particularly limited, but the cell amount of the bacterium represented by cfu is, for example, 0.1. : 99.9 to 99.9: 0.1, more preferably 1:99 to 99: 1, more preferably 10:90 to 90:10, and 30:70 to 90: 10. It is more preferable to set it to 70:30.
These may usually be in the range of content when distributed as an oral composition.

The composition of the present invention preferably further contains prebiotics. Prebiotics mainly refer to those showing an action of promoting the growth of probiotics in the intestine or suppressing the decrease thereof. In the present invention, those exhibiting an action of promoting the growth and / or suppressing the decrease of Bifidobacterium spp. Are particularly preferable.
Prebiotics include oligosaccharides (lacturose, galactooligosaccharides, fructooligosaccharides, xylooligosaccharides, isomaltooligosaccharides, raffinose, lactosucrose, soybean oligosaccharides, coffee oligosaccharides, human milk oligosaccharides, etc.), monosaccharides (galactose, mannose). Etc.), dietary fiber (inulin, alginic acid, etc.) and the like, of which oligosaccharides are more preferable, and lactulose is even more preferable.

The content of prebiotics in the composition of the present invention is not particularly limited, but may be, for example, 0.1 to 90% by mass of the entire composition. Alternatively, it can be 1 to 900 mg per 1 g of the composition.

The composition of the present invention can extend healthy life expectancy. "Healthy longevity" is an index advocated by the World Health Organization (WHO), and refers to the period obtained by subtracting the period of need for nursing care such as bedridden and dementia from the average life expectancy. Prolonging healthy life expectancy does not mean simply living a long life, but prolonging the period in which both the mind and body live in a healthy state. It can be rephrased as shortening the period of need for nursing care, and may be shortening the approximate period by delaying the onset or progression of bedridden or dementia.

It is preferable that the healthy life expectancy extending effect exerted by the composition of the present invention is due to the prevention and / or improvement of frailty. Here, prevention of frail includes prevention of frail and delay of occurrence of frail, and improvement of frail includes suppression of frail and delay of progress of frail.
"Frail" is a weakened state that is in between a healthy state and a state of impaired living function or a state requiring long-term care due to increased vulnerability to stress due to a decrease in physiological reserve in old age. It is a term to refer to (see: Statement by the Japan Geriatrics Society https://jpn-geriat-soc.or.jp/info/topics/pdf/20140513_01_01.pdf). Such a weakened state includes not only physical problems such as loss of agility in movement due to muscle weakness and easy to fall, but also mental and psychological problems such as cognitive dysfunction and depression, living alone and financial distress. It is a concept that includes social problems. Frail's condition is usually considered not irreversible, but reversible, which can be restored to a healthy state with appropriate intervention.

There is no unified standard for diagnosing frailty syndrome, but the Cardiovascular Health Study standard (CHS standard) based on the phenotypic model and the Frailty Index based on the defect accumulation model are known as the main methods, and their scores are It may be judged that the frailty is improved by the improvement. In addition, FRAIL scale and Edmonton Frail Scale, which have been shown to be valid as a simple evaluation method (FRAIL scale).
EFS), Tilburg Frailty Indicator (TFI), Basic Checklist (KCL), Simple Frail Index, etc. may determine the improvement of frail.

The Japanese version of the CHS standard (J-CHS) uses five items as evaluation criteria: "weight loss,""muscleweakness,""fatigue,""decreased walking speed," and "decreased physical activity."
As shown in Examples described later, since the appetite improving effect is recognized by ingesting the composition of the present invention, it is expected that the evaluation of "weight loss" will be improved. In addition, since the sleep improving effect and the fatigue recovery effect are recognized by ingesting the composition of the present invention, it is expected that the evaluation of "fatigue" will be improved. In addition, since the effect of increasing muscle mass is observed by ingesting the composition of the present invention, it is expected that the evaluation of "weakness", "decrease in walking speed", or "decrease in physical activity" will be improved.
Thus, the compositions of the present invention can prevent and / or improve flail from a physical and / or mental / psychological aspect, and as a result can extend healthy life expectancy.
It is presumed that such an effect can be obtained additively or synergistically by combining a bacterium belonging to the genus Bifidobacterium and a bacterium belonging to the genus Bifidobacterium.

Another aspect of the invention is the use of bifidobacteria and lacticase bacillus in the production of healthy life expectancy lengthening compositions.
Another aspect of the invention is the use of bifidobacteria and lacticase bacillus in extending healthy life expectancy.
Another aspect of the invention is the bacterium Bifidobacterium and the bacterium Lactica zeibacillus, which are used to extend healthy life expectancy.
Another aspect of the present invention is a method for extending healthy life expectancy, which comprises administering to a subject a bacterium belonging to the genus Bifidobacterium and a bacterium belonging to the genus Bifidobacterium.

The subject to which the composition of the present invention is administered (administrator) and the subject to be ingested (ingestor) are not particularly limited as long as they are animals, but are usually humans. Further, it may be any of adults, children, infants, newborns and the like, but it is usually an adult, preferably an elderly person (65 years old or older). The gender is not particularly limited.

In addition, in this specification, "administering a bacterium of the genus Bifidobacterium and a bacterium of the genus Bifidobacterium to an animal" is synonymous with "to ingest a bacterium of the genus Bifidobacterium and a bacterium of the genus Bifidobacterium". May be. Ingestion is usually voluntary (free ingestion), but may be compulsory (compulsory ingestion). That is, the administration step is specifically, for example, a step of blending Bifidobacterium spp. And Lactica zeibacillus spp. Into food and drink or feed and supplying the subject to the subject so that the subject can freely ingest it. There may be.

The ingestion (administration) timing of the composition of the present invention is not particularly limited, and can be appropriately selected according to the condition of the ingestion (administration) target.

The ingestion (administration) amount of the composition of the present invention is appropriately selected depending on the age, gender, condition, other conditions, etc. of the ingestion (administration) target.
The intake (administration) amount of the composition of the present invention is, for example, 1 × 10 ⁷ to 1 × 10 ¹² cfu / day as the intake (administration) amount of the bacterial cells of the genus Bifidobacterium according to the present invention. The range of 1 × 10 ⁸ to 1 × 10 ¹¹ cfu / day is preferable, and the range of 1 × 10 ⁹ to 1 × 10 ¹¹ cfu / day is even more preferable. In addition, the intake (administration) amount of the bacterial cells of the genus Bacillus lacticase is preferably in the range of 1 × 10 ⁷ to 1 × 10 ¹² cfu / day in adults, for example, 1 × 10 ⁸ to 1 × 10 ¹¹ cfu /. The range of days is more preferred, and 1 × 10 ⁹ to 1 × 10 ¹¹ cfu / day is even more preferred.
Alternatively, the intake (administration) amount of the culture supernatant of Bifidobacterium is preferably in the range of 0.5 to 5 g / day, more preferably in the range of 1 to 4 g / day, and 2 to 3 g in adults, for example. / Day is more preferred. The intake (administration) amount of the culture supernatant of the lactobacillus spp. Is preferably in the range of 0.5 to 5 g / day, more preferably 1 to 4 g / day, and 2 to 3 g / day in adults, for example. More preferred.
Regardless of the amount and duration of ingestion (administration), the composition of the present invention can be ingested (administered) once or divided into a plurality of times a day.

The ingestion (administration) period of the composition of the present invention is not particularly limited. In addition, there is no particular upper limit on the ingestion (administration) period, and continuous and long-term ingestion (administration) is possible.

The route of ingestion (administration) of the composition of the present invention may be oral or parenteral, but oral is preferable. In addition, parenteral ingestion (administration) includes transdermal, intravenous injection, rectal administration, inhalation and the like.

When the composition of the present invention is to be orally ingested (administered), it is preferably in the form of food and drink.

The form and properties of the food and drink are not particularly limited as long as they do not impair the effects of the present invention and can be orally ingested (administered), except that they contain bifidobacteria and lacticase bacillus. , Can be produced by a usual method using raw materials usually used for food and drink.

The food and drink may be in the form of liquid, paste, gel-like solid, powder, etc., for example, nutritional supplements, tablets; liquid foods (nutrient foods for tube intake); bread, macaroni, spaghetti. , Noodles, cake mix, fried flour, bread flour and other wheat flour products; instant noodles, cup noodles, retort / cooked foods, cooked cans, microwave foods, instant soups / stews, instant miso soups / soups, canned soups, freeze-dried foods , Other instant foods such as instant foods; canned agricultural products, canned fruits, jams and marmalades, pickles, boiled beans, dried agricultural products, processed agricultural products such as cereals (processed grain products); canned fishery products, fish hams and sausages , Seafood paste products, fishery delicacies, boiled fish and other marine products; canned livestock and pastes, processed livestock products such as meat ham and sausage; , Prepared milk powder, cream, other dairy products such as milk and dairy products; butter, margarines, vegetable oils and other fats and oils; soy sauce, miso, sauces, tomato processed seasonings, mirins, vinegars and other basic seasonings Beverages; Combined seasonings / foods such as cooking mixes, curry drinks, sauces, dressings, noodles, spices, and other complex seasonings; Ingredients Frozen foods, semi-cooked frozen foods, cooked frozen foods, etc. Frozen foods; caramel, candy, chewing gum, chocolate, cookies, biscuits, cakes, pies, snacks, crackers, Japanese confectionery, rice confectionery, bean confectionery, dessert confectionery, jelly, and other confectionery; carbonated beverages, natural fruit juice , Fruit juice drinks, soft drinks with fruit juice, fruit drinks, fruit drinks with fruit grains, vegetable drinks, soy milk, soy milk drinks, coffee drinks, tea drinks, powder drinks, concentrated drinks, sports drinks, nutritional drinks, alcoholic drinks, etc. Favorite beverages such as favorite beverages, baby foods, sprinkles, other commercially available foods such as Ochazuke paste; preparation powdered milk for childcare; enteral nutritional foods; functional foods (foods for specified health use, nutritional functional foods), etc. ..

It can also be used as feed as an aspect of food and drink. Examples of the feed include pet food, livestock feed, fish feed and the like.
The form of the feed is not particularly limited, and in addition to the bacteria of the genus Bifidobacterium and the genus Lactica zeibacils, for example, grains such as corn, wheat, barley, rye, and mylo; soybean oil cake, rapeseed oil cake, coconut oil cake, and flaxseed. Vegetable oil cakes such as oil cakes; bran such as bran, wheat bran, rice bran, defatted rice bran; production of corn gluten meal, corn jam meal, etc. Feeds; Yeasts such as tollula yeast and beer yeast; Mineral substance feeds such as tertiary calcium phosphate and calcium carbonate Feeds; Oils and fats; Single amino acids; Sugars and the like may be contained.

When the composition of the present invention is in the form of a food or drink (including feed), it can be provided and sold as a food or drink labeled for use in extending healthy life expectancy.

Such "display" actions include all actions for informing the consumer of the use, and if the expression is such that the use can be recalled or inferred, the purpose of the display, the content of the display, and the like. Regardless of the object or medium to be displayed, all of them fall under the "display" act in the present invention.
Further, it is preferable that the "display" is performed by an expression that allows the consumer to directly recognize the above-mentioned use. Specifically, the act of transferring a product related to food and drink or the packaging of the product that describes the above-mentioned use, displaying it for delivery, transfer or delivery, and importing it, advertising on the product, price list or transaction documents Examples include the act of describing the above-mentioned use and displaying or distributing it, or describing the above-mentioned use in the information containing these and providing it by an electromagnetic (Internet, etc.) method.

On the other hand, as the display content, it is preferable that the display is approved by the government or the like (for example, a display obtained based on various systems established by the government and performed in a mode based on such approval). In addition, it is preferable to attach such display contents to packaging, containers, catalogs, pamphlets, promotional materials such as POPs at sales sites, and other documents.

In addition, "labeling" includes labeling as health foods, functional foods, enteral nutrition foods, special purpose foods, health functional foods, specified health foods, nutritional functional foods, functionally labeled foods, non-pharmaceutical products, etc. Can also be mentioned. Among these, in particular, labeling approved by the Consumer Affairs Agency, for example, a system related to foods for specified health use, nutritionally functional foods, or foods with functional claims, or labeling approved by a system similar to these can be mentioned. Specifically, labeling as a food for specified health use, labeling as a food for specified health use conditionally, labeling to the effect that it affects the structure and function of the body, labeling for reducing the risk of illness, and functionality based on scientific evidence. Indications, etc. can be mentioned, and more specifically, Cabinet Office Ordinance on permission for special use indications stipulated in the Health Promotion Act (Cabinet Office Ordinance No. 57, August 31, 2001) Labeling as a food for specified health use (particularly labeling for health use) and similar labeling specified in the above are typical examples.

Examples of such indications include "for those who want to extend healthy life expectancy", "for prevention / improvement of mental and physical aging", "frailty measures", "frailty prevention" and the like.

Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples.

[Test Example 1] Examination of healthy life expectancy extending effect (1) Test method The administration test of the composition of the present invention to humans was carried out by the following procedure. This test was conducted at the Takara Clinic of the Medical Corporation Seishinkai in accordance with the purpose of the Declaration of Helsinki with the approval of the ethics committee of the clinic.
The subjects of administration were Japanese men and women at home aged 65 years or older who had 2 to 5 defecations per week, and obtained informed consent by fully explaining the contents of the study. The following conditions were used as exclusion criteria for participation in the test. (a) Those who are being treated or have a history of malignant tumors, (b) those who are being treated or have a history of autoimmune diseases, (c) those who are being treated or have a history of inflammatory bowel diseases, (d) ) Those who are in the hospital, (e) Those who regularly consume foods for specified health use and foods with functional claims, (f) Those who regularly consume natto, yogurt, foods / beverages containing lactic acid bacteria, (g) ) Smokers, (h) Those who regularly use anti-allergic drugs, (i) Those who regularly use laxatives, (j) Foods for specified health use, and those who regularly use supplements that are considered to be functional other than foods with functional claims. Those who have (k) allergies (pharmaceutical / test food related foods), (l) those who are pregnant, breastfeeding, or willing to become pregnant during the test period, (m) before the consent form acquisition date Those who participated in other clinical trials during the three months of (n) and others who were judged by the investigator to be inappropriate for this study.
The intake group included in the analysis was 28 (10 males, 18 females, 71.0 ± 4.5 years old).

The subjects were asked to ingest the test composition once daily after breakfast for 4 weeks. At the same time, a non-ingestion group (29 persons) who did not ingest the test composition was also provided.
The test composition is in powder form, and one serving (1.5 g) is Bifidobacterium longum NI.
It contained 10 billion live cells of TE BP-02621, 10 billion dead cells of Lactobacillus paracasei NITE BP-01633, 300 mg of lactulose, and 0.15 g of dietary fiber.
Various subjective symptoms were evaluated by a questionnaire (Likert scale method) before the start of ingestion and 4 weeks after the start of ingestion. The evaluation was made into 6 grades: 1: not applicable at all, 2: almost not applicable, 3: not very applicable, 4: slightly applicable, 5: fairly applicable, and 6: very applicable.
In addition, physical measurements and physical examinations were performed before the start of intake and 4 weeks after the start of intake. As one of them, muscle mass was measured using ZEUS 9.9 (manufactured by Kobe Medicare Co., Ltd.).

(2) Results Significant improvement was observed after ingestion of the test composition in the items of "I am worried because I can't sleep", "I have no appetite", and "I can't get tired even after taking a rest for 2 days". (Table 1). In addition, even in comparison with the non-ingestion group, a significant improvement was observed in the item "I can't get tired even after resting for 2 days" (P <0.008).
A significant increase in muscle mass was observed after ingestion of the test composition compared to before ingestion (Table 2). In addition, a significant increase in muscle mass was also observed in comparison with the non-ingestion group (P <0.017).

Claims (10)

A composition for extending healthy life expectancy, which comprises a bacterium belonging to the genus Bifidobacterium and a bacterium belonging to the genus Lacticaseibacillus. The composition according to claim 1, wherein the Bifidobacterium bacterium is Bifidobacterium longum. The Bifidobacterium longum is NITE.
The composition according to claim 2, which is BP-02621. The composition according to any one of claims 1 to 3, wherein the bacterium belonging to the genus Lacticaseibacillus is Lacticaseibacillus paracasei. The Lactobacillus paracasei is the Lactobacillus paracasei NITE.
The composition according to claim 4, which is BP-01633. The composition according to any one of claims 1 to 5, wherein the bifidobacteria and / or the lactobacillus bacterium are live bacteria and / or dead bacteria, respectively. The composition according to any one of claims 1 to 6, further comprising prebiotics. The composition according to claim 7, wherein the prebiotic is lactulose. The composition according to any one of claims 1 to 8, wherein the extension of healthy life expectancy is due to prevention and / or improvement of frailty. The composition according to any one of claims 1 to 9, which is a food or drink.